JP2005508368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508368A5 JP2005508368A5 JP2003541772A JP2003541772A JP2005508368A5 JP 2005508368 A5 JP2005508368 A5 JP 2005508368A5 JP 2003541772 A JP2003541772 A JP 2003541772A JP 2003541772 A JP2003541772 A JP 2003541772A JP 2005508368 A5 JP2005508368 A5 JP 2005508368A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- composition
- alkyl
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- 239000002552 dosage form Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 239000007903 gelatin capsule Substances 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000007910 chewable tablet Substances 0.000 claims 2
- 229940068682 chewable tablet Drugs 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000007938 effervescent tablet Substances 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- -1 hydroxy, amino, carboxyl Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000829 suppository Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000007911 effervescent powder Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34802001P | 2001-11-08 | 2001-11-08 | |
| PCT/US2002/035900 WO2003039480A2 (en) | 2001-11-08 | 2002-11-08 | Method of treating disorder related to high cholesterol concentration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508368A JP2005508368A (ja) | 2005-03-31 |
| JP2005508368A5 true JP2005508368A5 (enExample) | 2006-01-12 |
Family
ID=23366328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541772A Pending JP2005508368A (ja) | 2001-11-08 | 2002-11-08 | 高コレステロール濃度に関連した疾患の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1450816A4 (enExample) |
| JP (1) | JP2005508368A (enExample) |
| CA (1) | CA2466033A1 (enExample) |
| TW (1) | TW200300078A (enExample) |
| WO (1) | WO2003039480A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078396B2 (en) | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| CA2585623C (en) | 2004-10-27 | 2012-06-05 | Daiichi Sankyo Company Limited | Ortho-substituted benzene derivatives |
| CA2668661A1 (en) | 2006-11-13 | 2008-05-29 | Novartis Ag | Substituted pyrazole and triazole compounds as ksp inhibitors |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| CN107936076B (zh) * | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| AU2014243773B2 (en) | 2013-03-13 | 2018-12-13 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| MX2015012437A (es) * | 2013-03-13 | 2016-04-15 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones, y usos de los mismos. |
| JP2016193835A (ja) * | 2013-09-04 | 2016-11-17 | 学校法人常翔学園 | 核内受容体肝臓ｘ受容体アゴニスト |
| TWI734665B (zh) | 2013-12-24 | 2021-08-01 | 維吉尼亞聯邦大學 | 氧化膽固醇硫酸鹽（ｏｃｓ）之用途 |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA2991214C (en) | 2015-07-06 | 2024-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| MA44526A (fr) | 2016-04-01 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA45598B1 (fr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda |
| TWI815796B (zh) | 2016-08-02 | 2023-09-21 | 美商杜瑞克公司 | 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法 |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| US11111266B2 (en) | 2016-10-18 | 2021-09-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4976857A (enExample) * | 1972-12-06 | 1974-07-24 | ||
| US3963765A (en) * | 1973-04-01 | 1976-06-15 | Yehuda Mazur | Preparation of derivatives of cholesterol |
| US4217288A (en) * | 1977-03-24 | 1980-08-12 | Wisconsin Alumni Research Foundation | Anti-vitamin D compounds |
| JPS61254599A (ja) * | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| IL105050A0 (en) * | 1992-03-27 | 1993-07-08 | Lilly Co Eli | Steroid derivatives |
| IT1255241B (it) * | 1992-07-22 | 1995-10-20 | Simos Contos | Derivato di acido biliare e suo uso in terapia |
| MXPA01011070A (es) * | 1999-04-30 | 2003-06-30 | Arch Dev Corp | Derivados de esteroides. |
| DK1392713T3 (da) * | 2001-05-03 | 2008-02-18 | Univ Chicago | Lever-X-receptoragonister |
-
2002
- 2002-11-08 EP EP02802882A patent/EP1450816A4/en not_active Withdrawn
- 2002-11-08 WO PCT/US2002/035900 patent/WO2003039480A2/en not_active Ceased
- 2002-11-08 JP JP2003541772A patent/JP2005508368A/ja active Pending
- 2002-11-08 CA CA002466033A patent/CA2466033A1/en not_active Abandoned
- 2002-11-08 TW TW091132850A patent/TW200300078A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508368A5 (enExample) | ||
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| JP2008522981A5 (enExample) | ||
| JP2004523581A5 (enExample) | ||
| HUP0001894A2 (hu) | N-Piperidino-3-pirazolkarboxamid-származékot, sóját vagy szolvátját tartalmazó orálisan adagolható gyógyszerkészítmény | |
| JP2007502861A5 (enExample) | ||
| JP2008509166A5 (enExample) | ||
| JP2004529125A5 (enExample) | ||
| JP2003528852A5 (enExample) | ||
| EP1797878A3 (en) | Benzothiazole derivatives | |
| RU2001121186A (ru) | Производные пиразолкарбоновой кислоты, их получение, содержащие их фармацевтические композиции | |
| EP2210892A3 (en) | Neurologically-active compounds | |
| CA2498944A1 (en) | Amino alcohol derivatives, salts thereof and immunosuppressive agents | |
| JP2002520316A5 (enExample) | ||
| JP2005527576A5 (enExample) | ||
| HRP20151051T1 (hr) | Formulacije src/abl inhibitora | |
| JP2004532828A5 (enExample) | ||
| JP2007505044A5 (enExample) | ||
| JP2009040767A5 (enExample) | ||
| US20180370960A1 (en) | Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis Protein | |
| JP2017515899A (ja) | カンナビノイド受容体メディエータとしてのピラゾール誘導体およびそれらの使用 | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| RU2222537C2 (ru) | Новые производные морфолина, способ их получения и содержащие их фармацевтические композиции | |
| US7015238B2 (en) | Crystalline organic acid salt of amlodipine |